Compare Davita Inc (DVA) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs KB Financial Group, Inc. — how do they compare? Davita Inc trades at $178.24 (market cap $11.29B), while KB Financial Group, Inc. trades at $122.42 (market cap $42.62B). The key difference: KB Financial Group, Inc. is far larger — about 3.8× Davita Inc's market cap, and KB Financial Group, Inc. pays a 2.71% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and KB Financial Group, Inc. for 33 Days on average.
| DVA | KB | |
|---|---|---|
Market Cap | $11.29B | $42.62B |
Volume | 582,204 | 164,291 |
Sector | Health | Financials |
52-Week High | $240.96 | $132.88 |
52-Week Low | $103.87 | $77.50 |
Typical Hold Time | 113 Days | 33 Days |
Enterprise Value | $24.01B | $215.53T |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
KB Financial Group (KB) trades at $122.00, down 2.19% on the day, with neutral technical signals despite bullish moving averages. The company demonstrates strong fundamental performance with consistent earnings beats, revenue growth from $21.23T in 2025 to $22.37T projected for 2026, and healthy profit margins above 28%. Recent analyst upgrades to Strong Buy highlight momentum potential amid positive South Korean market sentiment.
The stock presents value characteristics with a P/E of 9.68 and P/B below 1.0, supported by robust cash flow generation. However, elevated EV/EBITDA at 21.71 and mixed analyst consensus (33% Buy, 67% Hold) suggest cautious optimism. Key risks include interest rate sensitivity given the banking sector exposure and potential macroeconomic headwinds affecting international operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
